Compare PACK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | SGHT |
|---|---|---|
| Founded | 1972 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 489.7M |
| IPO Year | 2017 | 2021 |
| Metric | PACK | SGHT |
|---|---|---|
| Price | $3.18 | $9.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $7.08 | ★ $10.17 |
| AVG Volume (30 Days) | ★ 613.1K | 296.5K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | $77,363,000.00 |
| Revenue This Year | $9.87 | $16.75 |
| Revenue Next Year | $9.00 | $11.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.05 | $3.38 |
| 52 Week High | $7.81 | $9.71 |
| Indicator | PACK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 59.53 |
| Support Level | N/A | $7.88 |
| Resistance Level | $4.40 | $9.71 |
| Average True Range (ATR) | 0.23 | 0.46 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 12.77 | 80.52 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.